![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Global Biopharmaceutical will Leverage Biorchestra Targeting Technology Platform, BDDS™ to Develop Nucleic Acid Therapies, including BMD-001, for Treatment of Neurological Disorders in Multiple Targets.
Lead Product(s): BMD-001
Therapeutic Area: Neurology Product Name: BMD-001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $861.0 million Upfront Cash: Undisclosed
Deal Type: Agreement March 27, 2023
Details:
BMD-001 (or BDDS : miR-485-3p ASO) is an antisense oligonucleotides encapsulated with proprietary Brin polymer to cross blood-brain barrier and plasma membrane of microglia, astrocyte and neuron to degrade the microRNA 485-3p and treat neuroinflammation and neurodegeneration.
Lead Product(s): BMD-001
Therapeutic Area: Neurology Product Name: BMD-001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
Under the collaboration agreement, BIORCHESTRA, that develops RNA therapeutics for neurodegenerative diseases, will be responsible for target discovery, selection, and synthesis via its in-house technology by using antisense oligonucleotides.
Lead Product(s): Antisense Oligonucleotides
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: SK Biopharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 05, 2022